Key result
Coagulation assays, particularly LD-dTT, showed good agreement with the UPLC-MS/MS reference method for measuring dabigatran concentrations in patients with atrial fibrillation.
Why the study?
Do coagulation assays accurately measure dabigatran concentrations compared to UPLC-MS/MS in patients with atrial fibrillation?
Observational (n=40)
Do coagulation assays accurately measure dabigatran concentrations compared to UPLC-MS/MS in patients with atrial fibrillation?
Coagulation assays, particularly LD-dTT, accurately measure pharmacologically active dabigatran concentrations including glucuronides, suggesting potential utility for therapeutic monitoring in AF patients.
Answers are grounded in this paper and cite their sources.
Supports LD-dTT for dabigatran monitoring in AF; leaves open prospective outcome validation before clinical adoption.
BACKGROUND: Dabigatran is prescribed to increasing numbers of patients with atrial fibrillation (AF). Although routine monitoring is not considered to be useful, measuring drug concentrations can be clinically relevant in specific situations. The aim of this study was the comparison of different functional and non-functional assays for determination of dabigatran concentrations at different timepoints in a real-life patient population with AF. We focused on the differences between assays in identifying patients with low drug concentrations. Furthermore, we studied the effect of glucuronidation on the established concentration as determined with different assays. METHODS: This study established dabigatran concentration ranges in 40 real-life AF patients by an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) reference method and compared these with results from coagulation assays (Hemoclot dTT, LD-dTT and ECA). Samples were taken just before and 2 and 4 h after taking the drug. RESULTS: A wide range of concentrations at different time points was found in this patient group. Coagulation assays correlate best with UPLC-MS/MS results that include the glucuronidated metabolites, showing that the pharmacologically active glucuronides are also measured in coagulation testing. The LD-dTT has the best agreement with UPLC-MS/MS and combines good sensitivity with high specificity. Several patients show consistently low or high drug concentrations, implying that drug exposure differs between patients. CONCLUSIONS: Based on the association of dabigatran concentrations with bleeding and thromboembolic risk, we believe that dabigatran monitoring could be beneficial for further optimizing anticoagulation therapy in AF.
No takes yet. Share an insight, caveat, or question.
Boonen et al. (2017) conducted an observational in Atrial fibrillation (n=40). Coagulation assays (Hemoclot dTT, LD-dTT, and ECA) vs. UPLC-MS/MS reference method was evaluated on Agreement of dabigatran concentrations between coagulation assays and UPLC-MS/MS. Coagulation assays, particularly LD-dTT, showed good agreement with the UPLC-MS/MS reference method for measuring dabigatran concentrations in patients with atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: